Zacks Research Has Bullish Forecast for GSK FY2024 Earnings

GSK plc (NYSE:GSK - Free Report) - Research analysts at Zacks Research boosted their FY2024 earnings per share estimates for shares of GSK in a report released on Tuesday, November 19th. Zacks Research analyst E. Bagri now anticipates that the pharmaceutical company will post earnings of $4.12 per share for the year, up from their previous forecast of $4.11. The consensus estimate for GSK's current full-year earnings is $4.03 per share. Zacks Research also issued estimates for GSK's Q1 2026 earnings at $1.14 EPS and Q3 2026 earnings at $1.57 EPS.

GSK has been the subject of a number of other reports. Guggenheim cut GSK from a "buy" rating to a "neutral" rating in a report on Thursday, October 31st. Jefferies Financial Group cut GSK from a "buy" rating to a "hold" rating and lowered their target price for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Argus raised shares of GSK to a "strong-buy" rating in a research note on Wednesday, August 7th. Barclays upgraded GSK to a "hold" rating in a report on Tuesday, August 27th. Finally, Deutsche Bank Aktiengesellschaft cut GSK from a "buy" rating to a "hold" rating in a research note on Friday, November 15th. Seven investment analysts have rated the stock with a hold rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $43.25.

GSK Trading Up 0.9 %

GSK traded up $0.30 during trading hours on Friday, reaching $34.00. The company's stock had a trading volume of 3,143,496 shares, compared to its average volume of 4,153,794. The business's 50-day moving average is $38.27 and its 200-day moving average is $40.44. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The stock has a market cap of $70.47 billion, a PE ratio of 21.87, a P/E/G ratio of 1.29 and a beta of 0.66. GSK has a fifty-two week low of $32.83 and a fifty-two week high of $45.92.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Shareholders of record on Friday, November 15th will be given a dividend of $0.3928 per share. This is a boost from GSK's previous quarterly dividend of $0.38. The ex-dividend date is Friday, November 15th. This represents a $1.57 annualized dividend and a yield of 4.62%. GSK's payout ratio is presently 98.70%.

Insider Activity

In related news, major shareholder Plc Gsk bought 2,791,930 shares of the stock in a transaction on Friday, September 27th. The shares were bought at an average cost of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the transaction, the insider now owns 16,775,691 shares of the company's stock, valued at $134,205,528. This represents a 19.97 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 10.00% of the company's stock.

Institutional Investors Weigh In On GSK

A number of institutional investors and hedge funds have recently modified their holdings of GSK. Eastern Bank acquired a new stake in shares of GSK during the 3rd quarter worth about $26,000. Sunbelt Securities Inc. grew its position in GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock valued at $29,000 after acquiring an additional 302 shares during the period. Concord Wealth Partners raised its holdings in shares of GSK by 231.8% in the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company's stock worth $32,000 after purchasing an additional 547 shares during the period. Ashton Thomas Private Wealth LLC acquired a new stake in GSK during the 2nd quarter worth approximately $37,000. Finally, Fortitude Family Office LLC purchased a new stake in GSK during the third quarter worth approximately $42,000. Institutional investors and hedge funds own 15.74% of the company's stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.